WWHC Stock Overview
W World Corp., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat a range of metabolic and nervous system disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
W World Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$2.00 |
| 52 Week Low | US$0.50 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -35.80% |
| 33 Year Change | -73.33% |
| 5 Year Change | -74.19% |
| Change since IPO | -99.99% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| WWHC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 0.3% |
| 1Y | -35.8% | 15.2% | 22.2% |
Return vs Industry: WWHC underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: WWHC underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| WWHC volatility | |
|---|---|
| WWHC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: WWHC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine WWHC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | n/a | www.pharmoscorp.com |
W World Corp., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat a range of metabolic and nervous system disorders. The company focuses on the disorders of the brain-gut axis, pain/inflammation, and autoimmune, as well as gout disorders. Its lead compounds under clinically development include Levotofisopam, a non-sedating agent for the treatment of Gout; and Dextofisopam, a non-serotonergic agent, which has completed Phase IIa and Phase IIb clinical trials for the treatment of irritable bowel syndrome.
W World Corp. Fundamentals Summary
| WWHC fundamental statistics | |
|---|---|
| Market cap | US$234.99k |
| Earnings (TTM) | -US$1.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs WWHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WWHC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.72m |
| Earnings | -US$1.72m |
Last Reported Earnings
Sep 30, 2012
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did WWHC perform over the long term?
See historical performance and comparison